Sanjay K. Juneja, MD

home / authors / sanjay-k-juneja-md

Sanjay K. Juneja, MD, is a medical oncologist at Mary Bird Perkins Cancer Center in Baton Rouge, Louisiana.

Articles

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Jordyn Sava;Sanjay K. Juneja, MD
January 15th 2025

In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

Innovative AI Approaches to Cancer Screening and Risk Assessment

Innovative AI Approaches to Cancer Screening and Risk Assessment

Sanjay K. Juneja, MD
December 24th 2024

Sanjay K. Juneja, MD, discusses how artificial intelligence is transforming early cancer screening.

AI’s Role in Revolutionizing Early Cancer Detection: Insights From Dr. Juneja

AI’s Role in Revolutionizing Early Cancer Detection: Insights From Dr. Juneja

Sanjay K. Juneja, MD
December 22nd 2024

Sanjay K. Juneja, MD, discusses how artificial intelligence has evolved in 2024 to help improve early detection of cancer.

Juneja Reflects on Becoming a Targeted Oncology 2024 Oncology Icon

Juneja Reflects on Becoming a Targeted Oncology 2024 Oncology Icon

Sanjay K. Juneja, MD
May 7th 2024

Sanjay K. Juneja, MD, delves into what being recognized as an oncology icon for Targeted Oncology means to him.

Education, Understanding, and Mentorship: The Rise of an Oncology Icon

Education, Understanding, and Mentorship: The Rise of an Oncology Icon

Sanjay K. Juneja, MD
April 25th 2024

Sanjay K. Juneja, MD, Targeted Oncology’s first 2024 Oncology Icon, delves into his background and what drove him to pursue a career in oncology.

Latest Updated Articles

ASH 2024 Preview for Community Oncologists: The Show and After Show
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Community Oncologists: The Show and After Show
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
FDA Oks Sotorasib/Panitumumab in KRAS G12C-Mutant Colorectal Cancer
Published: January 17th 2025 | Updated: January 22nd 2025
FDA Oks Sotorasib/Panitumumab in KRAS G12C-Mutant Colorectal Cancer
1 KOL is featured in this series.
Published: January 17th 2025 | Updated: January 22nd 2025
Upcoming Insights – Strategies for Management of Dermatological Reactions from Combination Amivantamab/ Lazertinib for EGFR-mutated NSCLC
Bridging Options for CAR T-Cell Therapy in R/R DLBCL
Published: January 6th 2023 | Updated: January 22nd 2025
Bridging Options for CAR T-Cell Therapy in R/R DLBCL
Challenging Disease Features of Myelofibrosis Lead to Use of JAK Inhibitors
Published: June 17th 2024 | Updated: January 22nd 2025
Challenging Disease Features of Myelofibrosis Lead to Use of JAK Inhibitors